Is NCT06008808 recruiting in St Louis, MO?

Yes, NCT06008808 is currently recruiting participants at its St Louis, MO location. This graft vs host disease clinical trial is actively enrolling qualified participants.

How do I join the graft vs host disease clinical trial in St Louis?

To join this clinical trial in St Louis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this St Louis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Graft Vs Host Disease Clinical Trial in St Louis, MO

About This Graft Vs Host Disease Study in St Louis

Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readily available haploidentical donors. One of the risks of a haploidentical HCT is graft vs. host disease (GVHD), but it is difficult to reduce the incidence of GVHD without compromising the graft vs. leukemia (GVL) effect. The hypothesis of this study is that JAK inhibition with and without CTLA-4 Ig with haploidentical HCT may mitigate GVHD and cytokine release syndrome while retaining the GVL effect and improving engraftment.

Sponsor: Washington University School of Medicine

Who Can Participate

Inclusion Criteria

Patients must meet the following criteria within 30 days prior to Day -3 unless otherwise noted.

Diagnosis of one of the hematological malignancies listed below:

Acute myelogenous leukemia (AML) in complete morphological remission, complete remission with incomplete hematologic recovery, and complete remission with partial hematologic recovery (based on ELN Criteria47).

Acute lymphocytic leukemia (ALL) in complete morphological remission (MRD negative by flow cytometry with sensitivity to ≤ 10-4).

Myelodysplastic syndrome with ≤ 10% blasts in bone marrow.

Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HD) in second or greater complete or partial remission.

Myelofibrosis with ≤ 10% blasts in bone marrow. Up to five patients with myelofibrosis will be permitted in Regimen 1 and up to five in Regimen 2.

AML in partial response. One patient will be enrolled in Regimen 1 given the prospect of potential benefit.

Planned treatment is T cell-replete peripheral blood haploidentical donor transplantation.

Available HLA-haploidentical donor who meets the following criteria:

Blood-related family member, including (but not limited to) sibling, offspring, cousin, nephew, or parent. Younger donors should be prioritized.

At least 18 years of age.

HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards.

In the investigator's opinion, is in general good health and medically able to tolerate leukapheresis required for harvesting hematopoietic stem cells.

No active hepatitis.

Negative for HTLV and HIV.

Not pregnant.

Donor selection will be in compliance with FDA guidelines as provided in 21 CFR 1271 for donor eligibility https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

Adequate organ function as defined below:

Total bilirubin ≤ 1.5 x IULN.

AST (SGOT) and ALT (SGPT) ≤ 3.0 x IULN.

Creatinine ≤ 1.5 x IULN OR creatinine clearance ≥ 45 mL/min/1.73 m2 by Cockcroft-Gault Formula.

Oxygen saturation ≥ 90% on room air.

LVEF ≥ 40%.

FEV1 and FVC ≥ 40% predicted, DLCOc ≥ 40% predicted. If DLCO is \< 40%, patients will still be considered eligible if deemed safe after a pulmonary evaluation.

Able to receive GVHD prophylaxis with tacrolimus, mycophenolate mofetil (if applicable), and cyclophosphamide.

At least 18 years of age at the time of study consent

The effects of ruxolitinib and abatacept on the developing human fetus are unknown. Additionally, tacrolimus may increase risk of hypertension, preeclampsia, preterm birth, and low birth weight; and mycophenolate mofetil is considered to be teratogenic. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of the study.

Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria

Prior allogeneic transplant (regardless of whether donor was related, unrelated, or cord). Prior autologous transplant is not exclusionary.

Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of ≥ 4000 as assessed by the single antigen bead assay.

Known HIV or active hepatitis B or C infection. Known current history of active tuberculosis.

Known hypersensitivity to one or more of the study agents.

Planning to receive antithymocyte globulin as part of the pre-transplant conditioning regimen.

Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (Day -3).

Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of Day -3.

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, autoimmune disease, symptomatic congestive heart failure, unstable angina pectoris, or unstable cardiac arrhythmias.

Immunosuppressive doses of steroids. Subjects with steroids for adrenal insufficiency will not be excluded.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in St Louis?

Yes, this clinical trial (NCT06008808) has an active research site in St Louis, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Graft Vs Host Disease Treatment Options in St Louis, MO

If you're searching for graft vs host disease treatment options in St Louis, MO, this clinical trial (NCT06008808) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our St Louis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced graft vs host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all graft vs host disease clinical trials near you to find additional studies recruiting in your area.

Graft Vs Host Disease Clinical Trial in St Louis, MO

Expert Care in St Louis

IRB Approved

No-Cost Care

Apply for This St Louis Location

Why Participate?

Simple Process